Novel Therapies in IgA Nephropathy Bring New Options, and New Questions

(MedPage Today) — Clinicians face exciting new options in immunoglobulin A (IgA) nephropathy, with recent accelerated FDA approvals and positive data presented on agents targeting B-cell activating factor (BAFF) and a proliferation-inducing ligand…